This browser is no longer supported

Please switch to a supported browser to continue using this website.
Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.

Partnering
Contact

Global Selector Contact Partnering Newsroom

We Are CSL
Patients & Public Health
R&D
Sustainability
Careers
Investors

We Are CSL
Patients & Public Health
R&D
Sustainability
Careers
Investors

Menu Section Title

Menu Section List

News

Home > Investors > News and Presentations > News / Media Releases

Recent Posts

CSL's Annual Research and Development Day Briefing
2021 CSL Centenary Fellowships Announced
Agreement to supply 51 mil vaccine doses
CSL’s Global Role in Battling COVID-19
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

Archives

October 2020
August 2020
July 2020

August 18th, 2020

CSL Media Statement on COVID19 Vaccine Manufacture

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

_{August 18th, 2020}

1

This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.

Introduction to CSL

See how we are driven by our promise.

Learn More

Board and Management

View our Board and Management here.

Learn More

Corporate Governance

View our corporate governance here.

Learn More

Terms of Use Cookie Policy Privacy Policy Accessibility Statement Sitemap

© CSL, All Rights Reserved